[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585720":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":36,"locations":42,"responsibleParty":63,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":78,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Constances volunteers",null,"The 2400 volunteers will be stratifed according to age in decades from 20 to 80 years of age and matched 1:1 male:female.",[13,14,15,16],"Radiation: Imaging examinations","Other: Paramedical examinations","Other: Medical examination","Other: Echocardiography",[18,23,28,32],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"RADIATION","Imaging examinations","* Cardiovascular MRI\n* Hepatic MRI\n* Hepatic ultrasound",[9],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"OTHER","Paramedical examinations","* Urinary pregnancy test for women of childbearing age.\n* Blood sample for cardiometabolism profiling\n* Blood samples for biobanking (according to the information and consent form)\n* Impedancemetry\n* AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device.",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Medical examination","* Review of risk factors\n* Review of previous history\n* Recording of current medication (dci, dose, start date)\n* Recording of medication in the last 6 months and discontinued since (dci, dose, start date)",[9],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"Echocardiography","Echocardiography including: 12-lead digital ECG",[9],[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Alban M Redheuil, PU-PH","CONTACT","+33142165545","alban.redheuil@aphp.fr",[43],{"facility":44,"status":45,"city":46,"state":10,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hôpital Pitié-Salpêtrière","RECRUITING","Paris","France","FR",{"type":50,"coordinates":51},"Point",[52,53],2.3488,48.85341,{"lat":53,"lon":52},[56,60],{"name":57,"role":39,"phone":58,"phoneExt":10,"email":59},"Louise M Meyfroit","+33182847789","l.meyfroit@ihuican.org",{"name":61,"role":39,"phone":10,"phoneExt":10,"email":62},"Yasmin Mokhtari","yasmin.mokhtari@inserm.fr",{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100585720","multimodal-cardiovascular-and-hepatic-population-imaging-100585720",false,"NCT06906042","Multimodal Cardiovascular and Hepatic Population Imaging","ICONIC","Inclusion Criteria:\n\n* Participation to the Constances cohort\n* Age ≥ 20 years\n* No overt cardiovascular or hepatic disease or related symptoms\n* No known family or personal genetic disease\n* Affiliation with a social security scheme or beneficiary of such a scheme.\n* Agreement to sign the consent\n\nExclusion Criteria:\n\n* Renal function impairment with GFR \\\u003C 60 mL\u002Fmin\u002F1.73m2\n* Deprived of liberty or persons subject to a legal protection measure (under guardianship or trusteeship)\n* People with contraindications to MRI (claustrophobia, presence of metallic elements…)\n* Pregnant or breastfeeding woman (pregnancy urinary test before inclusion for women of childbearing age).",true,"ALL","20 Years",{"count":76,"type":77},2400,"ESTIMATED","1 Day","OBSERVATIONAL","Medical imaging is increasingly important for understanding diseases, detecting them early, and personalizing treatments. New imaging techniques, which can measure processes in the body without surgery, are opening the door to a more precise approach to medicine. Instead of relying on general probabilities, this technology allows us to analyze specific factors in a person's health, leading to better predictions and targeted treatments. One key challenge in medicine today is reducing \"residual individual risk\"-the remaining health risks that current treatments don't fully address. This involves understanding how factors like age, sex, genetics, and environment affect our health, particularly when it comes to conditions like heart and liver disease. By using imaging to distinguish between normal aging and disease, we can better assess individual health risks.\n\nThe current project will create a large collection of medical images linked with health data from a broad population across France. Using advanced, non-invasive techniques such as MRI and ultrasound, researchers will analyze the heart, blood vessels, and liver in detail, considering factors like gender and health risk profiles. This will help improve our understanding of these diseases, which are often silent and not well understood, providing direct benefits to the participants. Ultimately, the goal is to optimize imaging technologies for large-scale studies, which will help enhance early detection and prevention for everyone.",[82,83],"Healthy Volunteers","Imaging Evaluation",[85,86,87,88,89,90,91,92,93],"multimodal imaging","heart","liver","Constances cohort","population","Cardiac imaging","MRI","Aging","reference values","2026-01-22",{"date":96,"type":97},"2026-01-23","ACTUAL",{"date":99,"type":97},"2025-09-15",{"date":101,"type":77},"2033-03-14",{"name":5,"class":6},1]